bioAffinity Technologies Presents Research Findings at CYTO 2023
22 May 2023 - 10:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a
biotechnology company addressing the need for noninvasive detection
of early-stage lung cancer and other diseases of the lung, today
will present the poster “Development of porphyrin-stained
polystyrene compensation beads for use on an automated analysis
platform” at CYTO 2023, the annual Congress for the International
Society for the Advancement of Cytometry (ISAC), in Montréal,
Québec, Canada. ISAC’s mission is to advance the impact of
cytometry to meet current and emerging challenges in the life,
biomedical and physical sciences.
Rossella Titone, Ph.D., Staff Scientist at bioAffinity
Technologies, will discuss the suitability of the Company’s
proprietary compensation beads for commercial use with flow
cytometry, including with CyPath® Lung, a noninvasive test for the
early detection of lung cancer. The poster will be displayed
throughout the CYTO conference.
bioAffinity Technologies’ diagnostic for early-stage lung
cancer, CyPath® Lung, uses flow cytometry to identify cell
populations in sputum that indicate cancer is present in the lung.
CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is
preferentially taken up by cancer and cancer-related cells. The
presence of a TCPP-labeled cell population is one of several cell
populations found to be indicative of lung cancer.
Unlike traditional microscopy-based cytology that is
labor-intensive and evaluates only a small fraction of a sample,
CyPath® Lung’s flow cytometry platform profiles an entire sputum
sample that contains millions of cells in minutes. The test’s
proprietary, AI-driven automated analysis of flow cytometric data
standardizes results and minimizes human error. A recent trial
resulted in 92% sensitivity and 87% specificity in the test’s
ability to detect lung cancer in individuals at high risk for the
disease who had small lung nodules less than 20 millimeters.
“bioAffinity Technologies’ porphyrin-labeled compensation beads
allow for accurate quantitation of TCPP fluorescence in cell
populations stained with TCPP,” said bioAffinity Technologies
Senior Vice President William Bauta, Ph.D., the inventor of the
compensation beads. “This work is part of our ongoing effort to
bring major advances in the detection and treatment of cancer to
the marketplace to improve survivability, reduce unnecessary
procedures and lower healthcare costs.”
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung, and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a laboratory developed test (LDT) by
Precision Pathology Services. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio. For more information, visit
www.bioaffinitytech.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230522005222/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Aug 2024 to Sep 2024
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Sep 2023 to Sep 2024